CX3CR1 and ovarian cancer: Interestingly, CX3CR1 overexpression has been associated to worse overall and reduced progression-free survival of platinum-, gemcitabine-, and topotecan-treated ovarian cancer patients [20], highlighting a prospective therapeutic strategy to restore sensitization by targeting CX3CR1.